Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
Type:
Grant
Filed:
January 29, 2021
Date of Patent:
September 14, 2021
Assignee:
Alpine Immune Sciences, Inc.
Inventors:
Ryan Swanson, Michael Kornacker, Mark F. Maurer, Joseph L. Kuijper
Abstract: The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses (e.g., innate and adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
Type:
Grant
Filed:
May 21, 2018
Date of Patent:
September 14, 2021
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventors:
Andrzej Myc, Ilona Kryczek, James R. Baker, Jr.
Abstract: The present invention relates to a method of treating and/or preventing cancer comprising administering a combination of an effective amount of a DNA hypomethylating agent and an effective amount of at least one immunomodulatory agent and/or optionally an effective amount of at least one targeted therapy agent.
Abstract: Provided are novel anti-SEZ6 antibodies and antibody drug conjugates, and methods of using such anti-SEZ6 antibodies and antibody drug conjugates to treat cancer.
Type:
Grant
Filed:
June 22, 2020
Date of Patent:
August 3, 2021
Assignee:
ABBVIE STEMCENTRX LLC
Inventors:
David Liu, Julia Gavrilyuk, Alexander Schammel
Abstract: Provided herein are methods for determining the functional status of a cellular pathway in a diseased cell sample obtained from an individual subject. These methods involve contacting a diseased cell sample obtained from the subject with a perturbing agent (e.g., an activating agent) known to perturb a specific cellular pathway when the pathway is functioning normally. A change in one or more physiological response parameters in the presence of the perturbing agent indicates that the cellular pathway targeted by the perturbing agent is functional in the individual subject. Methods of selecting a targeted therapeutic agent for an individual subject are also provided.
Type:
Grant
Filed:
June 10, 2016
Date of Patent:
July 27, 2021
Assignee:
Celcuity Inc.
Inventors:
Lance Gavin Laing, Brian Francis Sullivan
Abstract: Disclosed are improved yeast-based immunotherapeutic compositions comprising modified Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.
Type:
Grant
Filed:
August 1, 2016
Date of Patent:
July 20, 2021
Assignees:
GlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human Services
Inventors:
Thomas H. King, Zhimin Guo, Jeffrey Schlom, Claudia Palena
Abstract: The present disclosure relates to, among other things, antibody-drug conjugates comprising a STING agonist cyclic di-nucleotide conjugated to an antibody, preparation methods therefor, and uses therefor.
Type:
Grant
Filed:
July 20, 2020
Date of Patent:
June 15, 2021
Assignees:
ImmuneSensor Therapeutics, Inc., The Board of Regents of the University of Texas System
Abstract: A pharmaceutical composition comprising a cancer therapeutic that is capable of inhibiting and/or reducing the ability of a cancer cell to take up and utilize glucose or other energy source, a lipid or other building block of a cell membrane or organelle, and/or cholesterol. The pharmaceutical composition can comprise one or more cancer therapeutics that can be administered individually or in combination to an individual.
Type:
Grant
Filed:
May 30, 2018
Date of Patent:
June 8, 2021
Assignee:
Health Clinics Limited
Inventors:
Robin M. Bannister, John Brew, Gregory A. Stoloff
Abstract: In part, the disclosure relates to methods of treating fibrotic cancers by administering one or more Serum Amyloid Protein (SAP) agonists. In certain aspects, the method further comprises the conjoint administration of an anti-cancer therapeutic, e.g., a chemotherapeutic agent. In certain aspects, the disclosure relates to methods of treating myelofibrosis by administering an SAP agonist and optionally one or more anti-cancer therapeutic agents.
Type:
Grant
Filed:
October 8, 2014
Date of Patent:
June 1, 2021
Assignee:
PROMEDIOR, INC.
Inventors:
Suzanne Bruhn, Elizabeth Trehu, Mark Lupher, Jr.
Abstract: Compositions and methods for treatment of a condition associated with disease stem cells, and especially cancer stem cells are disclosed. In one aspect, a patient is treated with a stem cell differentiating agent and/or teratogenic pharmaceutical compound to induce one or more destructive pathways in the disease stem cells. Most typically, the destructive pathways include apoptotic pathways, necrotic pathways, and autophagy pathways.
Abstract: The invention provides an in vivo individualized systemic immunotherapeutic method and device. The method includes, in a non-sequential manner: (1) increasing release amount of tumor antigens at a tumor site; (2) at the tumor site, increasing level of proteins capable of adhering to and/or wrapping the tumor antigens; (3) at the tumor site, increasing level of dedicated antigen-presenting cells involved in immunity, and establishing, between the dedicated antigen-presenting cells and immune effector cells, a close connection capable of activating the immune effector cells; and (4) at the tumor site, increasing level and improving function of the immune effector cells. The steps (1)-(4) each reaches a maximum value at a respective time which overlaps with each other maximally, as well as at a respective site which overlaps with each other maximally. The invention combines oncolytic therapy and immunotherapy, in individualized systemic immunotherapy, and provides significantly improved therapeutic effect.
Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.
Abstract: Provided herein are methods for treating, preventing, and/or managing hematological cancers and solid tumors using combination therapy of 3-(5-amino-2-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione and checkpoint inhibitors.
Type:
Grant
Filed:
July 1, 2016
Date of Patent:
April 13, 2021
Assignee:
Celgene Corporation
Inventors:
Anita Gandhi, Hsiling Chiu, Michael Pourdehnad
Abstract: Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.
Type:
Grant
Filed:
October 25, 2016
Date of Patent:
April 13, 2021
Assignee:
Novartis AG
Inventors:
Alex Cortez, Bernhard Hubert Geierstanger, Timothy Z. Hoffman, Shailaja Kasibhatla, Tetsuo Uno, Xing Wang, Tom Yao-Hsiang Wu
Abstract: Disclosed are methods of isolating T cells having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation, the method comprising: identifying one or more genes in the nucleic acid of a cancer cell of a patient, each gene containing a cancer-specific mutation that encodes a mutated amino acid sequence; inducing autologous APCs of the patient to present the mutated amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated amino acid sequence; and selecting the autologous T cells. Also disclosed are related methods of preparing a population of cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.
Type:
Grant
Filed:
October 2, 2014
Date of Patent:
April 13, 2021
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human
Inventors:
Eric Tran, Yong-Chen Lu, Paul Robbins, Steven A. Rosenberg